| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | -0.089 | 0.01 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | -0.097 | 0.01 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.093 | 0.01 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.092 | 0.01 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | -0.086 | 0.01 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | -0.087 | 0.01 |
| mRNA | SNX-2112 | CTRPv2 | pan-cancer | AAC | -0.078 | 0.01 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.095 | 0.01 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | -0.07 | 0.02 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.085 | 0.02 |